In this work, we present a particle-based SEIR epidemic simulator as a tool to assess the impact of different vaccination strategies on viral propagation and to model sterilizing and effective immunization outcomes. The simulator includes modules to support contact tracing of the interactions amongst individuals and epidemiological testing of the general population. The particles are distinguished by age to represent more accurately the infection and mortality rates. The tool can be calibrated by region of interest and for different vaccination strategies to enable locality-sensitive virus mitigation policy measures and resource allocation. Moreover, the vaccination policy can be simulated based on the prioritization of certain age groups or randomly vaccinating individuals across all age groups. The results based on the experience of the province of Lecco, Italy, indicate that the simulator can evaluate vaccination strategies in a way that incorporates local circumstances of viral propagation and demographic susceptibilities. Further, the simulator accounts for modeling the distinction between sterilizing immunization, where immunized people are no longer contagious, and effective immunization, where the individuals can transmit the virus even after getting immunized. The parametric simulation results showed that the sterilizing-age-based vaccination scenario results in the least number of deaths. Furthermore, it revealed that older people should be vaccinated first to decrease the overall mortality rate. Also, the results showed that as the vaccination rate increases, the mortality rate between the scenarios shrinks.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843062 | PMC |
http://dx.doi.org/10.1109/JBHI.2021.3114180 | DOI Listing |
J Virol
December 2024
Department of Animal Science, Institute for Systems Genomics, University of Connecticut, Storrs, Connecticut, USA.
Unlabelled: Porcine reproductive and respiratory syndrome (PRRS) remains a major threat to animal health and causes substantial economic losses worldwide. The nonstructural protein 11 (NSP11) of the causative agent, PRRS virus (PRRSV), contains a highly conserved nidoviral uridylate-specific endoribonuclease (NendoU) domain essential for viral replication and immune evasion. Targeting NSP11 offers a novel approach to antiviral intervention.
View Article and Find Full Text PDFJ Clin Microbiol
December 2024
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA.
Unlabelled: Tongue swab (TS) sampling combined with quantitative PCR (qPCR) to detect (MTB) DNA is a promising alternative to sputum testing for tuberculosis (TB) diagnosis. In prior studies, the sensitivity of tongue swabbing has usually been lower than sputum. In this study, we evaluated two strategies to improve sensitivity.
View Article and Find Full Text PDFmSphere
December 2024
Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, China.
is a prominent Gram-negative and encapsulated opportunistic pathogen that causes a multitude of infections such as severe respiratory and healthcare-associated infections. Despite the widespread anti-microbial resistance and the high mortality rate, currently, no clinically vaccine is approved for battling . To date, messenger RNA (mRNA) vaccine is one of the most advancing technologies and are extensively investigated for viral infection, while infrequently applied for prevention of bacterial infections.
View Article and Find Full Text PDFEmerg Microbes Infect
January 2025
State Key Laboratory of Pathogenic Microorganisms, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Marburg virus disease (MVD) is a severe infectious disease characterized by fever and profound hemorrhage caused by the Marburg virus (MARV), with a mortality rate reaching 90%, posing a significant threat to humans. MARV lies in its classification as a biosafety level four (BSL-4) pathogen, which demands stringent experimental conditions and substantial funding. Therefore, accessible and practical animal models are urgently needed to advance prophylactic and therapeutic strategies for MARV.
View Article and Find Full Text PDFAnn Pharmacother
January 2025
ForHealth Consulting, UMass Chan Medical School, Shrewsbury, MA, USA.
Objective: The objective was to describe the pharmacology, efficacy, safety, and recommendations for the use of newly approved preventive agents and vaccines for respiratory syncytial virus (RSV) and discuss their uptake during the 2023 to 2024 RSV season.
Data Sources: A literature search of PubMed was performed (January 2020 to February 2024) with the search terms RSV vaccine, preventive antibody, and RSV prevention. Utilization data were collected from TriNetX using the US Collaborative Network (May 2024) using the terms palivizumab, nirsevimab, and RSV prefusion F protein.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!